The Ebola vaccine market includes products that protect against the Ebola virus disease in humans. The Ebola virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. Some key Ebola vaccines available in the market include rVSV-ZEBOV from Merck and Ad26.ZEBOV, MVA-BN-Filo from Johnson & Johnson. These vaccines help in promoting the development of immune response and protection against the Ebola virus. For instance, rVSV-ZEBOV has shown nearly 100% efficacy in preventing Ebola infection. The global Ebola vaccine market is estimated to be valued at US$ 6.72 billion in 2023 and is expected to exhibit a CAGR of 9.4% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
The global Ebola vaccine market is driven by rapid advancements in immune-protection therapies. Growing research aimed at developing more effective vaccines and therapies to combat Ebola infections has accelerated clinical research activities. Large clinical trials are being conducted to test vaccine efficacy and safety. Furthermore, rising investments by governments and international organizations to curb Ebola outbreaks in African countries are contributing to market growth. For instance, the Coalition for Epidemic Preparedness Innovations (CEPI) invested over $100 million in 2019 to support Ebola vaccine research.
Market Dynamics:
One of the key drivers for the Ebola vaccine market referred from the heading is rapid advancements in immune-protection therapies. The development of newer vaccine candidates with improved immunogenicity and protection profiles is expected to boost market growth over the forecast period. For instance, companies are developing vaccines based on viral-vector platforms such as measles vectored vaccines and adenovirus-vectored vaccines which induce longer lasting immune response against Ebola infection in comparison to first-generation vaccines.Furthermore, rising funding for Ebola vaccine research by global organizations will also promote development of novel and improved vaccine candidates in the market.
Segment Analysis
The global Ebola Vaccine Market Growth is dominated by the preventive vaccines segment. Preventive vaccines are administered to protect an individual before being exposed to the Ebola virus and are highly preferred for high-risk individuals like healthcare professionals, military personnel and travelers. Preventive Ebola vaccines provide protection against all four species of the Ebola virus that cause disease in humans – Bundibugyo virus, Sudan virus, Taï Forest virus and Zaire virus. They generate a strong immunologic response by inducing neutralizing antibodies against the whole surface glycoprotein of the viruses, thereby offering long-lasting immunity against the deadly disease.
PEST Analysis
Political: Governments across Africa and other high-risk regions have implemented immunization programs to curb Ebola outbreaks using preventive vaccines. Mass vaccination drives are organized during epidemics to contain the spread.
Economic: Rising awareness about the fatal consequences of Ebola epidemics is driving the demand and funding for efficient vaccines. Grants and donations from global health organizations help strengthen immunization infrastructure in underdeveloped regions.
Social: Social stigma and fear around Ebola continues to impact treatment-seeking behavior. Education programs emphasize the safety and effectiveness of preventive vaccines to boost community acceptance and vaccination rates.
Technological: Advancements in viral vector-based platform technologies have enabled the development of highly immunogenic vaccines providing durable protection against multiple Ebola virus strains with a single dose. DNA-based and mRNA vaccine formats offer flexibility in large-scale production.
Key Takeaways
The global Ebola vaccine market is expected to witness high growth over the forecast period driven by ongoing research into new prophylactic vaccines and booster doses.
North America currently dominates the market due to presence of key industry players and availability of advanced healthcare facilities to test new vaccine candidates. However, the Africa region is expected to emerge as the fastest growing regional market. Africa has faced recurring Ebola epidemics and a strong emphasis is placed on establishing regional manufacturing capabilities and immunization programs using affordable multi-dose Ebola vaccines.
Key players
operating in the Ebola vaccine market are 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode. These players are focusing on expanding their product portfolios by development of new vaccine formats such as DNA, mRNA and viral-vectored vaccines to protect against emerging Ebola virus strains.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it